Talent Bridge

Supporting global talent dedicated to advancing aging research

earthnightsc.png

What is Talent Bridge?

The Talent Bridge (TB) program by Norn Group identifies and supports global talent outside of the U.S. dedicated to advancing aging research.

Through extensive project support, mentorship, and access to the Longevity Nexus community, TB enables researchers to grow and innovate.

The program provides assistance with relocation to the U.S. if desired, allowing participants to maximize their contribution and impact.

The primary goals of the Talent Bridge program are to:

  1. Recruit and support exceptional global talent in aging research.

  2. Support innovative projects that advance the scientific understanding and application of longevity research.

  3. Facilitate their transition to the U.S. through financial support and visa facilitation.

  4. Build a strong, collaborative community of leading experts in aging research.

How does it work?

Participants are selected based on a proposal submission, where they are invited to present project ideas aligned with the mission of Norn Group. An ideal candidate is one that has and will continue demonstrate ambition and dedication towards pushing the aging field forward.
Upon successful application via our selection committee, participants will have the opportunity to join Norn Group’s Longevity Nexus (see Nexus to learn more) and upon successful presentation of their research or a milestone indicating progress, the participants can/will receive small awards in order to enable work on their project and fund logistical costs associated with propelling their career. 
Selected individuals will be expected to undertake at least one collaborative project with Norn Group, and may relocate to the U.S. as a part of their work, though this is flexible based on the timeline of their project. Norn Group will do its best to provide support during this transition through introductions with the Norn-network, connections with legal support and accommodation providers, and assistance navigating other nuances associated with relocation.

How can I participate?

Interested candidates can formally apply by submitting a project proposal outlining their work and its relevance to aging research (see form below). Candidates may also be invited to apply for the program based on their existing relationship with Norn Group.

The application process involves initial approval by Chief of Staff, Sufal Deb, and President, Martin Borch Jensen. Post initial approval, applicants will need to receive 4 out of 5 votes from the Talent Bridge Selection Committee to be eligible.

They will then be invited to join the Nexus community to further establish project milestones/deliverables based on their project’s desired output and impact to receive the award. Direct outreach may be considered for exceptional candidates interested in, or already working on relevant projects.

Project Proposals

All projects MUST be directly related to aging and longevity research. However they are not limited to the traditional STEM categories. All projects are expected to ultimately contribute to the advancement of knowledge and practical applications in the field, optimizing for Impact.

Topics can include (but are not limited to):

  • Innovative Scientific Research

  • Technology and Tool Development

  • Challenges and Improvements of Existing Aging Theories

  • Aging Policy Initiatives

  • Topics addressing our Open Calls and more

Apply Now!

Get in touch with us or fill out our application form below to get started! For more information, read through our Frequently Asked Questions below or get in touch with us.

Talent Bridge Selection Committee

  • Kumar Garg

    President of Renaissance Philanthropy

  • Laura Deming

    CEO at Cradle Health
    Co-Founder of Age1

  • Vadim Gladyshev

    Professor of Medicine Harvard Medical School
    Director of the Center for Redox Medicine

  • Martin Borch Jensen

    President of Norn Group
    CSO at Gordian Biotechnology

  • Adam Marblestone

    CEO at Convergent Research

 TB - FAQs